✦ LIBER ✦

Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein

✍ Scribed by Toshiyuki Itamoto; Hideki Nakahara; Hirotaka Tashiro; Naoki Haruta; Toshimasa Asahara; Akira Naito; Katsuhide Ito

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 209 KB
Volume: 80
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.10116

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hepatic arterial infusion chemotherapy f

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis : Analysis of 48 cases

✍ Eiji Ando; Masatoshi Tanaka; Fumihiko Yamashita; Ryoko Kuromatsu; Shigeru Yutani 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB

## Background: The prognosis of patients with hepatocellular carcinoma (hcc) with portal vein tumor thrombosis (pvtt) is extremely poor. the aim of this study was to elucidate the efficacy of hepatic arterial infusion chemotherapy (haic) for patients with advanced hccs. ## Methods: Forty-eight hc

Combined therapy consisting of intraarte

Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis

✍ Young-Hwa Chung; Il Han Song; Byung-Cheol Song; Geun Chan Lee; Moon Soo Koh; Hyu 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 1 views

## BACKGROUND. Hepatocellular carcinoma (HCC) patients with major vascular involvement or extrahepatic metastasis are not good candidates for surgery or transarterial chemoembolization (TACE). In this study, the authors evaluated the efficacy of combined therapy with intraarterial cisplatin infusio

Paclitaxel, cisplatin, and 5-fluorouraci

Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck

✍ Maha Hussain; Shirish Gadgeel; Omer Kucuk; Wei Du; Walter Salwen; John Ensley 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 3 views

## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi

Phase II trial of chemotherapy with 5-fl

Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type

✍ Abdelkrim Taamma; Abdelrahim Fandi; Nacer Azli; Pierre Wibault; Nadia Chouaki; A 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

## BACKGROUND. The aim of this study was to evaluate the toxicity and efficacy of the combination of 5-fluorouracil, bleomycin, epirubicin, and cisplatin (FBEC) in the treatment of patients with undifferentiated carcinoma of nasopharyngeal type (UCNT). The study included patients with metastatic or

A phase II evaluation of a 3-hour infusi

A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck : Southwest Oncology Group study 0007

✍ Francis P. Worden; James Moon; Wolfram Samlowski; Joseph I. Clark; Shaker R. Dak 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views